How much funding has Inhibikase Therapeutics raised?

Inhibikase Therapeutics has raised $110.0M in total funding, most recently a Private Equity round.

Who are Inhibikase Therapeutics's investors?

Inhibikase Therapeutics's investors include Soleus Capital, Sands Capital, Fairmount.

When was Inhibikase Therapeutics founded?

Inhibikase Therapeutics was founded in 2008.

Where is Inhibikase Therapeutics headquartered?

Inhibikase Therapeutics is headquartered in Atlanta, Georgia, United States.

What industry is Inhibikase Therapeutics in?

Inhibikase Therapeutics operates in Biotech, Healthcare.

How many employees does Inhibikase Therapeutics have?

Inhibikase Therapeutics has 11-50 employees.

Inhibikase Therapeutics

IPO

Inhibikase Therapeutics, Inc.

Public · Atlanta, United States · Founded 2008 · $110.0M raised

Biotech

Healthcare

Headquarters: Atlanta, Georgia
Employees: 11–50
Founded: 2008
Business Model: B2B
Website: inhibikase.com

Total Funding: $110.0M
Last Round: $110.0M Private EquityOct 2024
Rounds: 1
Type: Public

About

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of pulmonary arterial hypertension (PAH). The company applies Abelson Tyrosine Kinase inhibitor science to address serious cardiovascular and pulmonary diseases, advancing its lead candidate IkT-001Pro through late-stage clinical trials.

Summary

Inhibikase Therapeutics is a Biotech company based in Atlanta, United States, founded in 2008. It has raised $110.0M in total across 1 round, most recently a $110.0M Private Equity round in Oct 2024. Investors include Soleus Capital, Sands Capital and Fairmount.

LinkedIn X (Twitter)